Drug Search Results

TAK-285

Alternative Names: tak-285, tak285, tak 285
Latest Update: 2024-04-01
Latest Update Note: PubMed Publication

Product Description

TAK-285 is a novel low-molecular weight compound that was designed, synthesized by Takeda Pharmaceutical Company, Osaka, Japan, and has been shown to selectively and potently inhibit HER2 and EGFR kinase activities.Ê (Sourced from: https://drugs.ncats.io/drug/70CCB438L6)

Mechanisms of Action: EGFR Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Takeda
Company Location: TOKYO M0 103-8668
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for TAK-285

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 1: Oncology Unspecified

Trial	Phase	Trial Status	Disease	Primary Completion Date	Probability of Success
TAK-285_101	P1	Completed	Oncology Unspecified	2011-06-01

Recent News Events

Date	Type	Title
04/01/2024	PubMed	Synthesis of Indole-Linked Thiadiazoles and their Anticancer Action against Triple-Negative Breast Cancer.
12/01/2023	PubMed	Development of new TAK-285 derivatives as potent EGFR/HER2 inhibitors possessing antiproliferative effects against 22RV1 and PC3 prostate carcinoma cell lines.
05/06/2023	PubMed	Diosgenin and Monohydroxy Spirostanol from Prunus amygdalus var amara Seeds as Potential Suppressors of EGFR and HER2 Tyrosine Kinases: A Computational Approach.

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions